Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 InfectionThe New England journal of medicine, 2018-01, Vol.378 (4), p.354-369 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1702417 ;PMID: 29365309Full text available |
|
2 |
Material Type: Article
|
Heart and Lung Transplants from HCV-Infected Donors to Uninfected RecipientsThe New England journal of medicine, 2019-04, Vol.380 (17), p.1606-1617 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1812406 ;PMID: 30946553Full text available |
|
3 |
Material Type: Article
|
Screening and Treatment Program to Eliminate Hepatitis C in EgyptThe New England journal of medicine, 2020-03, Vol.382 (12), p.1166-1174 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsr1912628 ;PMID: 32187475Full text available |
|
4 |
Material Type: Article
|
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionThe New England journal of medicine, 2017-06, Vol.376 (22), p.2134-2146 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1613512 ;PMID: 28564569Full text available |
|
5 |
Material Type: Article
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionThe New England journal of medicine, 2015-12, Vol.373 (27), p.2608-2617 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1512612 ;PMID: 26575258Full text available |
|
6 |
Material Type: Article
|
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisThe New England journal of medicine, 2015-12, Vol.373 (27), p.2618-2628 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1512614 ;PMID: 26569658Full text available |
|
7 |
Material Type: Article
|
Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus ReplicationAntimicrobial agents and chemotherapy, 2019-02, Vol.63 (2) [Peer Reviewed Journal]Copyright © 2019 American Society for Microbiology. ;Copyright © 2019 American Society for Microbiology. 2019 American Society for Microbiology ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/AAC.01389-18 ;PMID: 30455237Full text available |
|
8 |
Material Type: Article
|
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyClinical infectious diseases, 2017-07, Vol.65 (1), p.6-12 [Peer Reviewed Journal]Copyright © 2017 Oxford University Press on behalf of the Infectious Diseases Society of America ;The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. ;Copyright Oxford University Press, UK Jul 1, 2017 ;The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2017 ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/cix260 ;PMID: 28369210Full text available |
|
9 |
Material Type: Article
|
Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney TransplantationAmerican journal of transplantation, 2016-05, Vol.16 (5), p.1474-1479 [Peer Reviewed Journal]Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons ;Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons. ;2016 the American Society of Transplantation and the American Society of Transplant Surgeons ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1600-6135 ;EISSN: 1600-6143 ;DOI: 10.1111/ajt.13518 ;PMID: 26587971Full text available |
|
10 |
Material Type: Article
|
Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia VasculitisGastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.49-52 [Peer Reviewed Journal]Attribution - NonCommercial ;ISSN: 0016-5085 ;EISSN: 1528-0012 ;DOI: 10.1053/j.gastro.2017.03.006 ;PMID: 28288791Digital Resources/Online E-Resources |
|
11 |
Material Type: Article
|
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisPLoS medicine, 2016-05, Vol.13 (5), p.e1002032-e1002032 [Peer Reviewed Journal]COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032 ;2016 World Health Organization 2016 World Health Organization ;2016 Public Library of Science. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. (2016) Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med 13(5): e1002032. doi:10.1371/journal.pmed.1002032 ;ISSN: 1549-1676 ;ISSN: 1549-1277 ;EISSN: 1549-1676 ;DOI: 10.1371/journal.pmed.1002032 ;PMID: 27243629Full text available |
|
12 |
Material Type: Article
|
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationScientific reports, 2017-01, Vol.7 (1), p.40920-40920, Article 40920 [Peer Reviewed Journal]Copyright Nature Publishing Group Jan 2017 ;Copyright © 2017, The Author(s) 2017 The Author(s) ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/srep40920 ;PMID: 28098253Full text available |
|
13 |
Material Type: Article
|
Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemicScientific reports, 2020-06, Vol.10 (1), p.9294-9294, Article 9294 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-66440-9 ;PMID: 32518317Full text available |
|
14 |
Material Type: Article
|
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyThe Lancet infectious diseases, 2015-09, Vol.15 (9), p.1049-1054 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 2015 ;ISSN: 1473-3099 ;EISSN: 1474-4457 ;DOI: 10.1016/S1473-3099(15)00157-7 ;PMID: 26187031 ;CODEN: LANCAOFull text available |
|
15 |
Material Type: Article
|
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)Journal of antimicrobial chemotherapy, 2022-02, Vol.77 (3), p.758-766 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0305-7453 ;EISSN: 1460-2091 ;DOI: 10.1093/jac/dkab433 ;PMID: 34849957Full text available |
|
16 |
Material Type: Article
|
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectivesLiver international, 2016-01, Vol.36 (S1), p.47-57 [Peer Reviewed Journal]2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ;2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. ;ISSN: 1478-3223 ;EISSN: 1478-3231 ;DOI: 10.1111/liv.13027 ;PMID: 26725897Full text available |
|
17 |
Material Type: Article
|
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and SimeprevirClinical infectious diseases, 2015-10, Vol.61 (8), p.1304-1306 [Peer Reviewed Journal]Copyright © 2015 Oxford University Press on behalf of the Infectious Diseases Society of America ;The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;ISSN: 1058-4838 ;EISSN: 1537-6591 ;DOI: 10.1093/cid/civ474 ;PMID: 26082511Full text available |
|
18 |
Material Type: Article
|
Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant RecipientsThe New England journal of medicine, 2016-11, Vol.375 (21), p.2106-2108 [Peer Reviewed Journal]Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc1611829 ;PMID: 27959735Full text available |
|
19 |
Material Type: Article
|
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral RegimensThe American journal of gastroenterology, 2016-06, Vol.111 (6), p.808-816 [Peer Reviewed Journal]Copyright Nature Publishing Group Jun 2016 ;ISSN: 0002-9270 ;EISSN: 1572-0241 ;DOI: 10.1038/ajg.2016.99 ;PMID: 27021197Full text available |
|
20 |
Material Type: Article
|
Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessmentPostgraduate medical journal, 2022-07, Vol.98 (1161), p.509 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;EISSN: 1469-0756 ;PMID: 37066509Full text available |